SEC Form CERT filed by Blue Water Acquisition Corp.

Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.'s common stock and warrants will commence trading on the Nasdaq Global Market on September 10, 2021, under the ticker symbols "CRXT" and "CRXTW," respectively Gross proceeds totaled approximately $25.3 million NORTHBROOK, Ill. and GREENWICH, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women (

GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ:BLUW), a special purpose acquisition company ("Blue Water"), today announced that its stockholders have voted to approve the proposed business combination (the "Business Combination") with Clarus Therapeutics, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women ("Clarus") at its special meeting of stockholders (the "Special Meeting") held today, August 27, 2021. Holders of approximately 73.95% of Blue Water's issued and outstanding shares cast votes at the Special Meeting. Approximately 69.57% o

NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ: BLUW) ("Blue Water" or the "Company"), a special purpose acquisition company (SPAC) that previously announced a planned business combination with Clarus Therapeutics, Inc. ("Clarus"), announced today that the special meeting of its stockholders (the "Special Meeting") originally scheduled for Thursday, August 12, 2021, is being postponed to Friday, August 27, 2021. As a result of this change, the Special Meeting will now be held at 10:00 a.m., Eastern Time, on August 27, 2021, exclusively via a live audio webcast at https://www.cstproxy.com/bluewateracquisition/2021. Also as a result of this c

4 - Blue Water Acquisition Corp. III (0002050501) (Issuer)

4 - Blue Water Acquisition Corp. III (0002050501) (Issuer)

8-K - Blue Water Acquisition Corp. III (0002050501) (Filer)

424B4 - Blue Water Acquisition Corp. III (0002050501) (Filer)

CERT - Blue Water Acquisition Corp. III (0002050501) (Filer)

4 - Blue Water Acquisition Corp. III (0002050501) (Issuer)

3 - Blue Water Acquisition Corp. III (0002050501) (Issuer)

3/A - Blue Water Acquisition Corp. III (0002050501) (Issuer)

SC 13G - Blue Water Acquisition Corp. (0001817944) (Subject)

SC 13G/A - Blue Water Acquisition Corp. (0001817944) (Subject)

SC 13G - Blue Water Acquisition Corp. (0001817944) (Subject)

GREENWICH, Conn., July 30, 2021 /PRNewswire/ --  Blue Water Acquisition Corp. (NASDAQ:BLUW) ("Blue Water"), a special purpose acquisition company ("SPAC") led by Joseph Hernandez, today announced that it has scheduled a special meeting of its stockholders (the "Special Meeting") to, among other things, consider and vote on a proposal to approve the transactions contemplated by the previously announced merger agreement pursuant to which Clarus Therapeutics, Inc. ("Clarus") will merge with a wholly-owned subsidiary of Blue Water (the "Business Combination") and seek to become a publicly listed company. Subject to stockholder approval and satisfaction of customary closing conditions, Clarus and